Chronic Liver Failure and Cirrhosis

Slide 1 · Chronic Liver Failure

and Cirrhosis

Pathogenesis • morphology • clinicopathologic correlation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish advanced fibrosis, cirrhosis, and chronic hepatic failure.

Explain how chronic injury produces nodules, scar, and altered hepatic blood flow.

Recognize gross and microscopic patterns of cirrhosis and regression.

Relate structural change to clinical dysfunction and major complications.

Slide 3 · Cirrhosis is a structural end point

Diffuse remodeling into parenchymal nodules, usually regenerative

Fibrous bands separating nodules throughout the liver

Variable intrahepatic and portosystemic vascular shunting

Slide 4 · Cirrhosis is not the same as liver failure

Cirrhosis

Chronic liver failure

Histologic/architectural diagnosis

Functional syndrome

Regenerative nodules plus diffuse fibrosis

Inadequate hepatic capacity to maintain homeostasis

May remain compensated

Usually reflects advanced, decompensated disease

Can be present without overt failure

Can arise without fully developed cirrhosis

Slide 5 · Anatomy, blood flow, and function are linked

Persistent injury

Fibrosis + nodules

Shunts and altered perfusion

Impaired hepatic function

Architecture mediates both mechanical resistance and metabolic dysfunction.

Slide 6 · Common causes of chronic liver failure

Worldwide leading causes

Shared final pathology

Chronic hepatitis B virus infection

Chronic hepatitis C virus infection

Metabolic dysfunction–associated steatotic liver disease

Alcohol-associated liver disease

Hepatocyte injury and cell loss

Repeated repair and regenerative attempts

Fibrosis and vascular remodeling

Variable functional decompensation

Slide 7 · Why the underlying etiology still matters

Cirrhosis describes architecture; It does not identify the initiating disease.

Untreated viral, alcohol-associated, steatotic, and metabolic diseases may have distinguishing features.

Inflammatory activity and the response to cause-directed treatment alter prognosis.

Morphology alone is insufficient to infer the same clinical trajectory for all etiologies.

Slide 8 · Cryptogenic cirrhosis is a descriptive label

The etiologic trigger is not identifiable in some cases.

“Cryptogenic” means cause not established, not a separate fibrotic mechanism.

Advanced remodeling can obscure findings of the original injury.

Slide 9 · End-stage liver disease need not be cirrhotic

Noncirrhotic examples

Interpretive point

Primary biliary cholangitis

Primary sclerosing cholangitis

Nodular regenerative hyperplasia

Chronic schistosomiasis

Fibropolycystic liver disease

Severe chronic injury may coexist with incomplete nodular/fibrous remodeling.

Use “end-stage liver disease” and “cirrhosis” precisely.

Slide 10 · Cirrhosis does not mean inevitable failure

Patients with successfully treated autoimmune hepatitis can remain stable.

Suppressed hepatitis B or cured hepatitis C can arrest progression.

Fibrotic architecture may persist despite control of the injurious process.

Slide 11 · Three interacting determinants of failure

Cell mass

Loss of functioning hepatocytes and impaired synthesis/metabolism

Architecture

Fibrosis and nodularity distort normal tissue organization

Perfusion

Shunting reduces delivery and exchange of portal blood

Slide 12 · Hepatic reserve delays clinical failure

Hepatocytes have substantial functional reserve and regenerative capacity.

Chronic disease can evolve silently despite extensive morphologic injury.

Failure becomes apparent when the remaining liver cannot sustain homeostasis.

Structural and functional severity must therefore be assessed separately.

Slide 13 · Repeated injury drives ineffective repair

Chronic injurious stimulus

Hepatocyte injury / loss

Regeneration + stellate activation

Collagen deposition and scarring

Mechanistic relationship — conceptual schematic

Slide 14 · Necrosis initiates tissue-level repair

Loss of membrane integrity allows hepatocyte swelling and rupture.

Macrophages remove cell debris and amplify local inflammatory signaling.

Confluent cell loss can collapse the reticulin scaffold.

A scar can replace the destroyed parenchymal framework.

Slide 15 · Parenchymal collapse helps form bridging scars

Confluent hepatocyte loss

Reticulin collapse

Myofibroblast collagen deposition

Fibrous septum

Sequence of tissue loss and repair, not a microscopic replica.

Slide 16 · Regeneration is a major compensatory response

Surviving mature hepatocytes normally replicate to replace lost cells.

Repeated chronic injury may eventually be accompanied by replicative senescence.

Residual hepatocytes proliferate in discrete islands constrained by fibrosis.

Regenerative activity does not by itself re-establish normal vascular organization.

Slide 17 · Ductular reaction accompanies altered repair

Ductlike cell structures expand in some chronically injured livers.

They can contain multipotent cells with potential to aid parenchymal repair.

Ductular reaction can remain conspicuous in morphologic regression.

It must be interpreted together with collagen pattern and background injury.

Slide 18 · Quiescent stellate cells have a storage role

Normal context

Chronic injury

Perisinusoidal hepatic stellate cells

Lipid storage, including vitamin A

Not the dominant scar-producing phenotype

Activation toward myofibroblast phenotype

Collagen and extracellular-matrix production

Fibrotic tissue remodeling

Slide 19 · Signals that activate hepatic stellate cells

Stellate-cell activation

Inflammatory cytokines

Altered extracellular matrix

Toxins and reactive oxygen species

Multiple inputs converge; Conceptual arrangement does not imply a linear biochemical order.

Slide 20 · Growth factors reinforce the profibrotic state

Signals emphasized

Cellular response

Platelet-derived growth factor (PDGF)

Transforming growth factor β (TGF-β)

Chemokines released by inflammatory cells

Stellate-cell differentiation toward myofibroblasts

Extracellular-matrix deposition

Autocrine and paracrine inflammatory signaling

Slide 21 · Collagen deposition alters the space of Disse

Perisinusoidal stellate activation

Extracellular-matrix accumulation

Altered sinusoid–hepatocyte interface

Reduced effective exchange

Mechanistic relationship — conceptual schematic

Slide 22 · Sinusoidal capillarization changes exchange

Normal sinusoid

Capillarized sinusoid

Fenestrated endothelial lining

Loss of endothelial fenestrations

Facilitates hepatocyte–blood exchange

Impedes normal exchange relationships

Minimal perisinusoidal scar

Increased matrix in the space of Disse

Slide 23 · Scar and regeneration reshape circulation

Collagen septa

Architectural distortion

Vascular remodeling / shunts

Altered hepatocyte perfusion

Mechanistic relationship — conceptual schematic

Slide 24 · The fibrotic process may regress

Removal of the initiating injury limits further stellate activation.

Matrix-degrading metalloproteinases can remodel collagen septa.

Fibrous tissue may partially resolve after viral control or alcohol cessation.

Morphologic regression is not proof that the original vascular network is restored.

Slide 25 · Incomplete septal cirrhosis signals regression

Established scar

Regression-associated scar

Thick fibrous septa

Thin, incomplete fibrous remnants

Conspicuous enclosed nodules

Less complete septal enclosure

Active or historical chronic injury

Architectural effects may outlast collagen loss

Slide 26 · Vascular injury can outlast scar regression

Residual intrahepatic shunts or vascular remodeling may persist.

Portal hypertension does not necessarily resolve with collagen resorption.

Tissue appearance and hemodynamic recovery are not interchangeable.

Slide 27 · Cirrhosis has three core morphologic features

Diffuse fibrosis

Bands of collagen distributed across the liver

Parenchymal nodules

Hepatocyte islands, commonly regenerative

Architectural remodeling

Loss of the normal relationship of lobules and vessels

Slide 28 · Gross appearance: Nodules and depressed scars

Schematic — not histologic or gross specimen

Bulging regenerative nodules produce an irregular capsule.

Fibrous scar produces depressed clefts between nodules.

The normally smooth surface becomes diffusely bumpy.

Slide 29 · The gross cut surface reflects compartmentalization

Schematic — not histologic or gross specimen

Fibrous bands partition hepatocyte-rich parenchyma.

Nodule sizes and scars vary within and between etiologies.

Color and gross texture alone do not specify the cause.

Slide 30 · Microscopy: Nodules enclosed by collagen

Schematic — not histologic or gross specimen

Parenchymal islands are separated by dense fibrous septa.

Normal lobular architecture is disrupted.

Fibrosis and regeneration coexist in the same tissue.

Slide 31 · Bridging fibrosis can connect different landmarks

Schematic — not histologic or gross specimen

Portal-to-portal fibrous bridging may occur.

Portal-to-central bridging is another recognized pattern.

Bridge configuration varies by the initiating liver disease.

Slide 32 · Nodule size is a variable, not a unique diagnosis

Regenerative nodules are not uniform in diameter.

Scars can form broad or thin septa in a single liver.

Different liver diseases produce partially overlapping morphologies.

Etiology requires integration of clinical history and additional pathology.

Slide 33 · Parenchymal loss adds a collapse component

Active tissue loss

Established scar

Confluent hepatocyte dropout

Residual collapsed reticulin scaffold

Macrophage-rich cleanup phase

Myofibroblast-derived collagen

Fibrous septa following tissue loss

Distortion of surviving hepatocyte plates

Slide 34 · Portal venous thrombosis modifies remodeling

The extent of vascular thrombosis varies across cirrhotic livers.

Portal venous occlusion can further alter local hepatic perfusion.

Vascular lesions should be assessed in addition to fibrosis and nodules.

Vascular injury can help explain discordant structural and functional findings.

Slide 35 · Regression has recognizable structural clues

Schematic — not histologic or gross specimen

Septal collagen may become thin and incomplete.

Ductular reaction may remain evident.

Persistent architectural remodeling limits a simple “reversal” label.

Slide 36 · Advanced chronic injury forms a spectrum

Chronic hepatocellular injury

Incomplete fibrous remodeling

Established cirrhosis

Variable regression or decompensation

Schematic continuum; Individual trajectories may diverge and are not always linear.

Slide 37 · Etiology influences but does not define pattern

Recognized causes

Compare in each specimen

Chronic viral hepatitis

Alcohol-associated liver disease

Steatotic liver disease

Inherited or acquired metabolic disease

Scar pattern and nodule architecture

Remaining injury and inflammation

Vascular thrombosis and collapse

Evidence of regression

Slide 38 · Collagen stains clarify fibrotic architecture

A collagen stain can outline fibrous septa more clearly than routine sections.

Assess whether collagen surrounds nodules and bridges landmarks.

Staining demonstrates structure; It does not establish the initiating etiology.

Slide 39 · A disciplined morphology review

Gross assessment

Microscopic assessment

Capsular contour and diffuse nodularity

Nodule-size variability

Depressed scar distribution

Fibrous septa and bridging pattern

Residual injury or parenchymal collapse

Ductular reaction and vascular change

Slide 40 · Compensated cirrhosis may be clinically silent

Approximately 40% of people with cirrhosis remain asymptomatic until advanced stages.

Absence of symptoms does not exclude substantial architectural disease.

Clinical presentation reflects functional reserve and complications as well as scar.

Slide 41 · Early symptomatic disease can be nonspecific

Anorexia and involuntary weight loss are common presentations.

Weakness and reduced functional capacity may dominate.

These findings do not identify the cause or prove liver failure.

Progressive organ dysfunction produces more distinctive manifestations.

Slide 42 · Failure has excretory, synthetic, and neurologic effects

Biliary excretion

Bilirubin retention and jaundice; Chronic cholestatic itching

Protein synthesis

Hypoalbuminemia and impaired coagulation factor synthesis

Metabolic clearance

Encephalopathy associated with impaired toxin handling

Slide 43 · Cholestasis explains jaundice and pruritus

Impaired bile formation / flow

Retention of bilirubin and other solutes

Jaundice + persistent pruritus

Excoriation and infection risk

Mechanistic relationship — conceptual schematic

Slide 44 · Severe pruritus can be debilitating

Persistent cholestasis may produce intense itching.

Repeated scratching causes skin excoriations and secondary infection risk.

The symptom burden can be marked even when gross structural changes are longstanding.

In severe refractory cases, relief may require transplantation.

Slide 45 · Synthetic dysfunction produces systemic effects

Albumin

Coagulation proteins

Reduced hepatocyte albumin synthesis

Loss of an important plasma oncotic contributor

Can accentuate fluid accumulation

Reduced production of multiple clotting factors

Prolongation of clotting assays

Bleeding vulnerability in advanced dysfunction

Slide 46 · Encephalopathy reflects altered metabolism

Gut-derived ammonia

Reduced hepatic processing / shunting

Brain dysfunction

Altered behavior → confusion → coma

Mechanistic relationship — conceptual schematic

Slide 47 · Asterixis is a characteristic neurologic sign

Brief, nonrhythmic lapses of maintained posture produce flapping motion.

It is classically elicited with wrists dorsiflexed and arms extended.

It supports an encephalopathic syndrome but is not exclusive to liver disease.

Slide 48 · Impaired hormone metabolism has visible effects

Reduced estrogen metabolism

Hyperestrogenemia

Cutaneous vascular changes

Reproductive endocrine effects

Mechanistic relationship — conceptual schematic

Slide 49 · Palmar erythema reflects altered vasomotor tone

Hyperestrogenemia is associated with vascular dilation in the palms.

The sign is a systemic consequence of altered hepatic metabolism.

It is supportive rather than pathognomonic.

Slide 50 · Spider angiomas have recognizable vascular anatomy

Central arteriole

Schematic — not histologic or gross specimen

A central pulsating, dilated arteriole is surrounded by radiating vessels.

Hyperestrogenemia is a contributor in chronic liver failure.

This superficial vascular finding is not itself a portosystemic shunt.

Slide 51 · Hypogonadism differs by sex and mechanism

Males

Females

Hyperestrogenemia can contribute to hypogonadism and gynecomastia

Disruption of the hypothalamic–pituitary axis may cause hypogonadism

Abnormal estrogen handling is prominent

Nutrition and primary hormonal disturbances may contribute

Slide 52 · Scarred architecture raises portal resistance

Fibrous septa + nodules

Sinusoidal flow obstruction

Increased intrahepatic resistance

Portal hypertension

Mechanistic relationship — conceptual schematic

Slide 53 · Portosystemic shunting weakens hepatic clearance

Vascular collaterals permit portal blood to bypass normal liver exchange.

Hepatocyte exposure to gut-derived substances is reduced.

Shunting can aggravate hepatic encephalopathy independent of hepatocyte loss.

Slide 54 · Complications of portal hypertension

Ascites

Fluid accumulation due to portal and systemic changes

Varices

Fragile collateral veins, notably esophagogastric

Splenomegaly

Congestion with possible hypersplenism

Encephalopathy

Reduced hepatic clearance through shunts

Slide 55 · Ascites is a multi-mechanism complication

Peritoneal fluid accumulation

Increased sinusoidal pressure

Splanchnic vasodilation

Low plasma oncotic support

Convergent contributors; The boxes represent parallel mechanisms, not a single ordered cascade.

Slide 56 · Esophagogastric varices cause major hemorrhage

Portosystemic collateral vessels enlarge in chronic portal hypertension.

Esophagogastric varices are particularly important clinically.

Variceal rupture can produce life-threatening hematemesis.

Variceal bleeding is a major cause of cirrhosis-related death.

Slide 57 · Splenomegaly can produce cytopenias

Portal venous congestion

Congestive splenomegaly

Blood-cell sequestration

Thrombocytopenia ± pancytopenia

Mechanistic relationship — conceptual schematic

Slide 58 · Bacterial infection is a major mortality driver

Chronic liver failure impairs host defenses.

Damage to the intestinal mucosal barrier.

Kupffer-cell dysfunction contributes to vulnerability.

Bacterial infection is among the major causes of death.

Slide 59 · Hepatocellular carcinoma is a critical complication

Hepatocellular carcinoma is a major cause of death in cirrhosis.

Background disease etiology remains relevant to oncogenic risk.

A new suspicious nodule requires consideration distinct from ordinary regenerative nodules.

Slide 60 · Clinical deterioration has multiple pathways

Loss of function

Jaundice, encephalopathy, coagulopathy

Portal complications

Ascites, variceal bleeding, splenomegaly

Infection / neoplasia

Bacterial infection and hepatocellular carcinoma

Slide 61 · Laboratory tests interrogate different functions

Test group

What it primarily reflects

AST, ALT

Hepatocyte injury/integrity

Bilirubin, ALP, GGT

Excretory and biliary abnormalities

Albumin, prothrombin time

Hepatic synthetic capacity

Ammonia

Metabolic handling in appropriate clinical context

Slide 62 · Aminotransferases are injury markers

AST and ALT signal hepatocellular injury rather than overall functional reserve.

Low or modest enzyme activities do not rule out advanced cirrhosis.

Synthetic and excretory parameters answer different clinical questions.

Interpret laboratory patterns with architecture and symptoms.

Slide 63 · Failure and cirrhosis require separate assessments

Architectural assessment

Functional assessment

Fibrous bands and parenchymal nodules

Jaundice / excretory impairment

Collapse and ductular reaction

Coagulopathy / impaired synthesis

Shunts and vascular remodeling

Encephalopathy / metabolic dysfunction

Slide 64 · Case: Suppressed hepatitis B and cirrhosis

Clinical stem

A patient with previous hepatitis B has stable laboratory indices after effective viral suppression. Imaging continues to describe a nodular liver.

Does persistent cirrhotic architecture prove ongoing chronic liver failure?

No. Cirrhosis may persist in a compensated patient after the injurious stimulus is controlled. Structural diagnosis and functional state must be reported separately.

Slide 65 · Case: Bleeding from collateral vessels

Clinical stem

An individual with established cirrhosis develops sudden hematemesis. Prior laboratory tests showed only modest abnormalities.

Which pathologic change can explain catastrophic bleeding?

Portal vascular resistance and portosystemic collateral formation can produce fragile esophagogastric varices, even when earlier tests did not suggest profound synthetic dysfunction.

Slide 66 · Case: Apparent improvement after abstinence

Clinical stem

Serial liver biopsies following prolonged abstinence demonstrate thinner, incomplete fibrous septa and less collagen than an earlier biopsy.

Which inference is justified—and which is not?

Scar regression is plausible. Complete restoration of vascular architecture, disappearance of portal hypertension, or cure of every complication cannot be assumed.

Slide 67 · Case: End-stage disease without classic nodules

Clinical stem

A patient has advanced primary sclerosing cholangitis with severe chronic liver dysfunction, but pathology does not show diffuse, fully established cirrhotic nodules.

Is “end-stage liver disease” necessarily equivalent to cirrhosis?

No. Some chronic cholangiopathies reach advanced disease without fully established cirrhosis. The terms should not be conflated.

Slide 68 · The histology–physiology chain

Injury and failed repair

Diffuse collagen septa + nodules

Flow diversion and diminished reserve

Failure + portal complications

Mechanistic relationship — conceptual schematic

Slide 69 · High-yield clinicopathologic synthesis

Cirrhosis = diffuse nodular regeneration and fibrosis with vascular remodeling.

Chronic liver failure is a functional syndrome, not a synonym for cirrhosis.

Stellate-cell–driven fibrosis may regress, while vascular abnormalities persist.

The major threats are encephalopathy, variceal hemorrhage, infection, and hepatocellular carcinoma.

Slide 70 · Primary reference and scope

Principal textbook

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition (2026).

Chapter 18, Liver and Gallbladder: Chronic Liver Failure and Cirrhosis (pp. 753–754).

Scope and visual evidence

Context integrated from preceding Scar Formation and Regression / Liver Failure and adjacent Portal Hypertension sections.

Gross and histology concepts are depicted as original, editable schematics; no textbook micrographs reproduced.